|
SciSparc Ltd. (SPRC): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
SciSparc Ltd. (SPRC) Bundle
In the cutting-edge world of neurological therapeutics, SciSparc Ltd. (SPRC) emerges as a pioneering force, leveraging cannabinoid-based innovations to transform treatment landscapes for complex neurological disorders. By combining groundbreaking research, proprietary drug delivery platforms, and a strategic focus on unmet medical needs, this Israeli-based pharmaceutical company is positioning itself at the forefront of neurological and psychiatric treatment breakthroughs. Investors and medical professionals alike are closely watching SciSparc's journey as it develops potentially revolutionary solutions for conditions like Tourette syndrome and other central nervous system challenges.
SciSparc Ltd. (SPRC) - Marketing Mix: Product
Cannabinoid-Based Therapeutic Solutions
SciSparc Ltd. specializes in developing pharmaceutical cannabinoid treatments for neurological and psychiatric disorders.
| Product Category | Key Details |
|---|---|
| Primary Drug Candidate | SCI-110 for Tourette syndrome |
| Delivery Platform | SPR206 proprietary targeted cannabinoid drug delivery system |
| Research Focus | Central Nervous System (CNS) conditions |
Product Portfolio
- SCI-110 clinical-stage therapeutic solution
- SPR206 drug delivery platform
- Innovative cannabinoid-based pharmaceutical research
Research and Development Characteristics
SciSparc focuses on neurological disorder treatments utilizing advanced cannabinoid technologies.
| R&D Metric | Current Status |
|---|---|
| Clinical Stage Compounds | 1 primary drug candidate (SCI-110) |
| Patent Applications | Multiple proprietary cannabinoid delivery technologies |
| Research Investment | Approximately $5.2 million in 2023 R&D expenses |
Therapeutic Target Areas
- Tourette syndrome
- Neurological disorders
- Psychiatric conditions
Unique Product Differentiators
Specialized in targeted cannabinoid drug delivery with innovative pharmaceutical approach.
SciSparc Ltd. (SPRC) - Marketing Mix: Place
Headquarters and Global Presence
Headquartered at 8 Haamal Street, Tel Aviv, Israel 6706867.
Distribution Channels
| Channel Type | Description | Market Coverage |
|---|---|---|
| Direct Sales | Pharmaceutical research networks | United States, Europe |
| Research Partnerships | Clinical development collaborations | International academic institutions |
Target Markets
- United States neurological treatment market
- European neurological treatment markets
- Global clinical research networks
Strategic Partnerships
Key Collaboration Institutions:
- Tel Aviv University
- University of California research networks
- European Neurological Research Centers
Operational Reach
Research and development operations spanning multiple international locations with primary focus on neurological treatment development.
SciSparc Ltd. (SPRC) - Marketing Mix: Promotion
Conference Presentations
SciSparc Ltd. actively participates in key neuroscience and pharmaceutical conferences to showcase its research and product developments.
| Conference Type | Frequency | Target Audience |
|---|---|---|
| Neuroscience Conferences | 2-3 per year | Researchers, Neurologists, Pharmaceutical Professionals |
| Pharmaceutical Industry Events | 1-2 per year | Investors, Medical Professionals, Pharmaceutical Executives |
Investor Relations and Scientific Publications
The company leverages scientific publications and investor relations channels to enhance brand visibility.
- Publishes research findings in peer-reviewed journals
- Maintains active investor relations communication
- Shares scientific data through professional networks
Press Release and Communication Strategy
SciSparc communicates research progress through strategic press releases and investor communications.
| Communication Channel | Frequency | Primary Purpose |
|---|---|---|
| Press Releases | 4-6 per year | Research Updates, Clinical Trial Progress |
| Investor Communications | Quarterly | Financial Performance, Strategic Developments |
Medical and Scientific Community Outreach
Targeted outreach to medical and scientific professionals is a key promotion strategy.
- Collaborates with academic research institutions
- Engages in professional medical symposiums
- Participates in scientific research networks
Digital Platform Engagement
SciSparc utilizes digital platforms for scientific and investor communication.
| Digital Platform | Engagement Metrics | Primary Audience |
|---|---|---|
| 2,500+ professional followers | Scientific Community, Investors | |
| Company Website | 10,000+ monthly visitors | Researchers, Investors, Medical Professionals |
SciSparc Ltd. (SPRC) - Marketing Mix: Price
Stock and Financial Overview
As of January 2024, SciSparc Ltd. (SPRC) trades on NASDAQ with the following financial metrics:
| Financial Metric | Value |
|---|---|
| Stock Price (Close) | $0.79 |
| Market Capitalization | $14.63 million |
| 52-Week Low | $0.46 |
| 52-Week High | $1.97 |
Pricing Strategy Considerations
SciSparc's pricing strategy is fundamentally tied to its pharmaceutical development pipeline, specifically cannabinoid-based therapeutic treatments.
- Primary focus on developing treatments for neurological disorders
- Research and development stage with no current commercial product revenue
- Valuation driven by potential therapeutic breakthrough value
Clinical Development Pricing Factors
Potential pricing influenced by:
| Development Stage | Pricing Impact |
|---|---|
| Preclinical Research | Minimal direct pricing |
| Phase I Clinical Trials | Initial value assessment |
| Phase II Clinical Trials | Increased investor interest |
| Regulatory Approval | Potential commercial pricing model |
Investment Metrics
Current investment characteristics:
- Cash and Cash Equivalents: $10.2 million (Q3 2023)
- Research Expenditure: $4.5 million annually
- Burn Rate: Approximately $1.1 million per quarter
Therapeutic Product Pricing Potential
Potential therapeutic product pricing based on market comparables:
| Therapeutic Area | Estimated Annual Treatment Cost |
|---|---|
| Neurological Disorders | $15,000 - $25,000 |
| Psychiatric Conditions | $10,000 - $18,000 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.